About
Wa'el Hashad is a pharmaceutical and biotechnology executive best known for serving as Chief Executive Officer of Longeveron from March 1, 2023 until the company announced his departure on September 3, 2025. His background includes senior operating roles at Avanir Pharmaceuticals, Seres Therapeutics, Amgen, Boehringer Ingelheim, and Eli Lilly. He has also served as an independent director at Akari Therapeutics and has been associated with California Life Sciences and Morningside Biopharma.
Areas of interest
biotechregenerative medicinecell therapyaging and longevityrare diseasedrug commercializationbusiness developmentcardiovascularneurosciencemicrobiome therapeutics